HRP20221018T1 - Liječenje katapleksije - Google Patents

Liječenje katapleksije Download PDF

Info

Publication number
HRP20221018T1
HRP20221018T1 HRP20221018TT HRP20221018T HRP20221018T1 HR P20221018 T1 HRP20221018 T1 HR P20221018T1 HR P20221018T T HRP20221018T T HR P20221018TT HR P20221018 T HRP20221018 T HR P20221018T HR P20221018 T1 HRP20221018 T1 HR P20221018T1
Authority
HR
Croatia
Prior art keywords
compound
formula
use according
enantiomer
carbon atoms
Prior art date
Application number
HRP20221018TT
Other languages
English (en)
Croatian (hr)
Inventor
Moise A. Khayrallah
Gary Bream
Stephen E. Butts
Original Assignee
Jazz Pharmaceuticals Ireland Limited
Sk Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20221018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jazz Pharmaceuticals Ireland Limited, Sk Biopharmaceuticals Co., Ltd. filed Critical Jazz Pharmaceuticals Ireland Limited
Publication of HRP20221018T1 publication Critical patent/HRP20221018T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02Carbamic acids; Salts of carbamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20221018TT 2013-03-13 2014-03-12 Liječenje katapleksije HRP20221018T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
EP14778088.6A EP2968208B1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy
PCT/US2014/023969 WO2014164969A1 (en) 2013-03-13 2014-03-12 Treatment of cataplexy

Publications (1)

Publication Number Publication Date
HRP20221018T1 true HRP20221018T1 (hr) 2023-01-06

Family

ID=51530017

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221018TT HRP20221018T1 (hr) 2013-03-13 2014-03-12 Liječenje katapleksije

Country Status (21)

Country Link
US (7) US9359290B2 (enExample)
EP (1) EP2968208B1 (enExample)
JP (2) JP6530741B2 (enExample)
KR (1) KR102192554B1 (enExample)
CN (1) CN105431142B (enExample)
AU (1) AU2014248849B2 (enExample)
BR (1) BR112015022197B1 (enExample)
CA (1) CA2905457A1 (enExample)
DK (1) DK2968208T3 (enExample)
ES (1) ES2927675T3 (enExample)
HR (1) HRP20221018T1 (enExample)
HU (1) HUE060060T2 (enExample)
MX (1) MX381381B (enExample)
MY (1) MY177740A (enExample)
PH (1) PH12015502075A1 (enExample)
PT (1) PT2968208T (enExample)
RU (2) RU2689984C2 (enExample)
SG (1) SG11201507121RA (enExample)
SI (1) SI2968208T1 (enExample)
TW (2) TWI663971B (enExample)
WO (1) WO2014164969A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006133393A1 (en) * 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
BR112015022197B1 (pt) * 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia
CN110638804A (zh) 2013-07-18 2020-01-03 爵士制药国际Iii有限公司 治疗肥胖
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CA3036071A1 (en) 2016-09-06 2018-03-15 Jazz Pharmaceuticals International Iii Limited Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN110049966A (zh) 2016-10-06 2019-07-23 杰资制药国际三期有限公司 氨基甲酰基苯丙氨醇化合物及其用途
JP2020528075A (ja) 2017-06-02 2020-09-17 ジャズ ファーマシューティカルズ アイルランド リミテッド 過度の眠気を処置するための方法および組成物
CA3071779A1 (en) 2017-07-31 2019-02-07 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
AU2018331326A1 (en) * 2017-09-12 2020-03-19 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
KR20210071046A (ko) * 2018-10-15 2021-06-15 액섬 테라퓨틱스, 인크. 기면증 치료를 위한 레복세틴의 용도
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
CA3163505A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
ZA943862B (en) 1993-06-10 1995-12-04 Lilly Co Eli Method of preventing emesis and treating sexual dysfunction using tetrahydrobenz[cd] indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
PT873308E (pt) 1996-10-10 2002-06-28 Sk Corp Compostos de o-carbamoil-fenilalaninol seus sais farmaceuticamente uteis e processo para a preparacao dos mesmos
WO1998017636A1 (en) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
MXPA06011410A (es) * 2004-03-31 2007-04-20 Johnson & Johnson Compuestos heterociclicos sin imidazol como moduladores de receptor de histamina h3.
BRPI0515645A (pt) * 2004-09-07 2008-03-04 Orphan Medical Inc métodos terapêuticos, composições, compostos e usos de compostos
CA2587481A1 (en) 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
WO2006133393A1 (en) 2005-06-08 2006-12-14 Sk Holdings Co., Ltd. Treatment of sleep-wake disorders
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
EP1928451B1 (en) 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
KR20090082213A (ko) 2006-10-13 2009-07-29 얀센 파마슈티카 엔.브이. 페닐알킬아미노 카바메이트 조성물
CA2669088C (en) * 2006-11-10 2016-04-05 Dimerix Bioscience Pty Ltd Detection system and uses therefor
KR20120098578A (ko) 2009-06-22 2012-09-05 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
ES2743153T3 (es) 2009-11-06 2020-02-18 Sk Biopharmaceuticals Co Ltd Métodos para tratar el síndrome de fibromialgia
US8895609B2 (en) 2009-11-06 2014-11-25 Sk Biopharmaceuticals Co., Ltd. Methods for treating attention-deficit/hyperactivity disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
BR112015022197B1 (pt) * 2013-03-13 2022-06-07 Sk Biopharmaceuticals Co., Ltd. Uso de um composto para o tratamento de cataplexia

Also Published As

Publication number Publication date
MX381381B (es) 2025-03-12
PT2968208T (pt) 2022-10-28
CA2905457A1 (en) 2014-10-09
KR20150139522A (ko) 2015-12-11
EP2968208A4 (en) 2016-10-12
AU2014248849A1 (en) 2015-10-08
AU2014248849B2 (en) 2018-08-30
TW201919606A (zh) 2019-06-01
US20140275244A1 (en) 2014-09-18
TW201513856A (zh) 2015-04-16
DK2968208T3 (da) 2022-08-22
MX2015012644A (es) 2016-06-21
US20160250176A1 (en) 2016-09-01
US20230416195A1 (en) 2023-12-28
TWI663971B (zh) 2019-07-01
CN105431142B (zh) 2019-04-26
RU2019114940A (ru) 2019-06-28
PH12015502075B1 (en) 2016-01-18
JP2019147830A (ja) 2019-09-05
JP2016512531A (ja) 2016-04-28
US20250059135A1 (en) 2025-02-20
MY177740A (en) 2020-09-23
US20170137375A1 (en) 2017-05-18
KR102192554B1 (ko) 2020-12-18
BR112015022197A8 (pt) 2019-11-26
EP2968208B1 (en) 2022-07-20
BR112015022197B1 (pt) 2022-06-07
JP6530741B2 (ja) 2019-06-12
ES2927675T3 (es) 2022-11-10
HUE060060T2 (hu) 2023-01-28
HK1219236A1 (zh) 2017-03-31
SI2968208T1 (sl) 2023-02-28
US9359290B2 (en) 2016-06-07
EP2968208A1 (en) 2016-01-20
PH12015502075A1 (en) 2016-01-18
RU2015143610A (ru) 2017-04-20
US20220017457A1 (en) 2022-01-20
WO2014164969A1 (en) 2014-10-09
SG11201507121RA (en) 2015-10-29
US12162821B2 (en) 2024-12-10
US11713292B2 (en) 2023-08-01
TWI684450B (zh) 2020-02-11
US20190218174A1 (en) 2019-07-18
US10259780B2 (en) 2019-04-16
RU2689984C2 (ru) 2019-05-30
US9585863B2 (en) 2017-03-07
RU2019114940A3 (enExample) 2019-12-25
CN105431142A (zh) 2016-03-23
BR112015022197A2 (pt) 2017-07-18
RU2015143610A3 (enExample) 2018-03-21
US11072579B2 (en) 2021-07-27

Similar Documents

Publication Publication Date Title
HRP20221018T1 (hr) Liječenje katapleksije
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
HRP20200561T1 (hr) Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti
BR112014025564A2 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
ME02490B (me) Hemijska jedinjenja
MX2016006919A (es) Nucleotidos para el tratamiento de cancer de higado.
HRP20211392T1 (hr) INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
MX2015010971A (es) Derivado novedoso de pirazol.
NZ716840A (en) Combination formulation of two antiviral compounds
MX2009008935A (es) Moduladores de las propiedades farmacocineticas de productos terapeuticos.
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
RU2015155585A (ru) 4-алкинилимидазольное производное и лекарственное средство, включающее такое производное в качестве активного ингредиента
BR112013017302A2 (pt) formulações de imunossupressor
MX336505B (es) Metodos y composiciones para reducir la grasa y los adipocitos del cuerpo.
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MX2009007914A (es) Composiciones farmaceuticas novedosas.
PH12015502429A1 (en) Dicarboxylic acid compound
EA201391537A1 (ru) ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5
MX2018006225A (es) Composicion farmaceutica para el tratamiento o prevencion de esteatohepatitis no alcoholica (nash).
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
MY183953A (en) Ethynyl derivatives
PH12017501750A1 (en) 6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors